Results 141 to 150 of about 26,553 (248)

Novel insights into extracellular vesicles: An update on biomolecules, immunomodulation and clinical strategies in skin melanoma

Clinical and Translational Medicine, Volume 16, Issue 4, April 2026.
Extracellular vesicles mediate melanoma progression by transferring biomolecules (proteins, nucleic acids) that reshape the tumour microenvironment, promote immune evasion and drive metastasis. They also serve as diagnostic biomarkers and engineered therapeutic carriers for targeted therapy.
Junshu Li, Wencheng Zhou, Ying Cen, Yong Qing   +3 more
wiley   +1 more source

Rationale and Design of the Cancer Immunotherapy Evidence Living (CIEL) Library: A Continuously Updated Clinical Trial Database of Cancer Immunotherapies

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Immunotherapies for cancers are tested in large numbers of clinical trials. It is difficult for clinicians and researchers to stay current with the evidence, and traditional systematic reviews and clinical guidelines are not suited to ensure a continued overview of all trials and their results.
Kim Boesen, Julian Hirt, Pascal Düblin, Heinz Läubli, Benjamin Kassenda, Lars G. Hemkens, Perrine Janiaud   +6 more
wiley   +1 more source

Zika virus has oncolytic activity against glioblastoma stem cells [PDF]

, 2017
Diamond, Michael S, et al,, Tycksen, Eric   +2 more
core   +2 more sources

Enhancing Oncolytic Adenovirus Replication by Early Region 1A Protein‐Mediated Degradation of E1A Binding Protein p300

MedComm, Volume 7, Issue 4, April 2026.
E1A is an important protein for adenovirus to initiate viral replication. Previous reports have shown that E1A binds to p300 as a regulatory factor. However, our study provides a new perspective that E1A promotes oncolytic adenovirus replication by degrading p300.
Boduan Xiao, Qingzhe Yang, Shichuan Hu, Jianchuan Hu, Zhongbing Qi, Yao Zhang, Yu Qin, Ping Cheng   +7 more
wiley   +1 more source

Isocitrate Dehydrogenase‐Mutant Astrocytomas: Risk Stratification and Therapeutic Advance

MedComm, Volume 7, Issue 4, April 2026.
This graphical abstract synthesizes the core logic of our revised review by linking integrated diagnosis, risk stratification, and trajectory‐based management in IDH‐mutant astrocytomas across CNS WHO Grades 2–4. It highlights lineage‐defining molecular classification (IDH mutation with core co‐alterations), integrated histomolecular grading, and key ...
Shepeng Wei, Xuxu Xu, Jing Bao, Zhenjiang Pan   +3 more
wiley   +1 more source

Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer

MedComm, Volume 7, Issue 4, April 2026.
This review summarizes recent advances in nanoparticle‐ and cell‐mediated OVs delivery strategies that improve biodistribution and tumor targeting while limiting immune clearance. It also examines combination approaches that enhance therapeutic efficacy through tumor microenvironment modulation or immune activation, thereby overcoming immunosuppression
Sikan Jin, Yi Zhang, Ziling Zhou, Yaqi Zhang, Ting Yu, Rui Xu, Lin Xu, Jidong Zhang, Longze Zhang, Shan Yang, Xianyao Wang   +10 more
wiley   +1 more source

Combination of Vaccine With IL‐12‐Armed Oncolytic Virus SKV‐012 Synergistically Potentiates Immune Responses in HPV‐Associated Malignancies

MedComm, Volume 7, Issue 4, April 2026.
A synergistic immunotherapeutic platform based on the intratumoral delivery of oncolytic virus and intramuscular vaccination activates both local and systemic antitumor immunity. This synergistic approach expands the universality and therapeutic efficacy of vaccines in HPV‐associated malignancies.
Nian Yang, Long Xu, Meijun Zheng, Huaqing Lu, Yongdong Chen, Zhixiong Zhu, Wanqin Zeng, Zeng Wang, Hexian Li, Jia Li, Zheng Jiang, Pingfu Zeng, Guoqing Wang, Hai Xie, Zongliang Zhang, Hui Yang, Aiping Tong   +16 more
wiley   +1 more source

Neoadjuvant therapy in skin cancer: current evidence and future perspectives

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 4, Page 454-462, April 2026.
Summary The development of immune checkpoint inhibitors and targeted therapies has fundamentally changed the treatment of cutaneous malignancies, especially in squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The latest neoadjuvant approaches have shown promising results in locally advanced stages.
Lea Daniello, Johannes Kleemann, Bastian Schilling   +2 more
wiley   +1 more source

Engineering megakaryocytes with oncolytic viruses for <i>in situ</i> generation of therapeutic platelets. [PDF]

Mol Ther Oncol
Yang Y, Gu Z, Yu J.
europepmc   +1 more source

Oncolytic viruses: advanced strategies in cancer therapy. [PDF]

Signal Transduct Target Ther
Xiao D, Zhang H, Liu Y, Li Y, Li G, Ning Y.   +5 more
europepmc   +1 more source